By Sriparna Roy (Reuters) -Akero Therapeutics shares gained 106% before the bell on Monday, after its lead drug showed it can ...
Researchers at Tel Aviv University have achieved a breakthrough in drug delivery: they have successfully transported lipid ...
Akero reported Monday strong results showing its drug efruxifermin reversed liver scarring in patients with cirrhosis caused ...
"Everything injected into the bloodstream is eventually ends up in the liver — that's just how our anatomy works," Professor ...
PEOPLE TAKING GLP-1S have a reduced risk of heart attacks, strokes, and death from cardiovascular disease, according to a ...
Akero Therapeutics shares traded near their all-time high as the drugmaker reported positive results in a study of its treatment for liver disease.
13don MSN
A common antihistamine may offer hope for patients with a rare genetic disease that can lead to severe liver damage and ...
SGLT-2 inhibitors vs DPP-4 inhibitors were associated with a reduced risk for liver cirrhosis among patients with type 2 diabetes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results